Aspartate
18 benefits mapped to clinical evidence across supplements.
Dose per serving from products
741 products in our catalogue print how much Aspartate a serving holds.
Most common: 1 g to 2.5 g, 35% of 741 products.
| Dose per serving | Products |
|---|---|
| 50 mg or less | 32 |
| 50 mg to 100 mg | 16 |
| 100 mg to 250 mg | 34 |
| 250 mg to 500 mg | 52 |
| 500 mg to 1 g | 84 |
| 1 g to 2.5 g | 263 |
| 2.5 g to 5 g | 228 |
| over 5 g | 32 |
Benefit Evidence
Ketamine: mood ↓14
Ketamine: rapid response
Metabolic/plasticity mood lift
Albumin/muscle synthesis +37%
Arginine: collagen/IGF-1 +52%
Nitrogen balance improved
Albumin/muscle synthesis +37%
Arginine: collagen/IGF-1 +52%
Nitrogen balance improved
Research sources
Nutrition source (83)
- Coadministration of ketoconazole to cyclosporin-treated kidney transplant recipients: a prospective randomized study
PubMed ID: 8546171
Adding low‑dose ketoconazole to cyclosporin therapy significantly reduced AST/ALT — direct, measurable improvement in liver chemistry.
- Effect of ursodeoxycholic acid on hypertransaminasaemia and bile acid composition in patients undergoing bone marrow transplantation--a double-blind randomized control study
PubMed ID: 8842833
UDCA accelerated normalization of liver enzymes after bone marrow transplant — clear benefit to blood liver chemistry.
- Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C
PubMed ID: 8938538
Stainable hepatic iron was associated with substantially higher AST/ALT and greater fibrosis — important observational blood chemistry association.
- Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients
PubMed ID: 9737807
Troglitazone produced clear improvements in fasting glucose and insulin — relevant blood chemistry changes.
- Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia
PubMed ID: 9761083
Extended‑release niacin produced robust LDL/HDL changes and documented transaminase effects — strong blood chemistry impact.
- Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial. Spanish Group for the Study of Alcoholic Fatty Liver
PubMed ID: 9537864
Metadoxine improved aminotransferases, GGT and ultrasound steatosis — substantial hepatic blood chemistry improvements.
- Antioxidant treatment during liver resection for alleviation of ischemia-reperfusion injury
PubMed ID: 9684133
Antioxidant vitamins reduced transaminase elevations and improved a coagulation test after ischemic injury — clear biochemical effects.
- Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients
PubMed ID: 10524635
Glycyrrhizin + UDCA lowered liver enzymes more than glycyrrhizin alone — meaningful changes in liver blood tests.
- Efficacy and safety of 300 micrograms and 400 micrograms cerivastatin once daily in patients with primary hypercholesterolaemia: a multicentre, randomized, double-blind, placebo-controlled study
PubMed ID: 10505301
Cerivastatin produced significant LDL reductions with no meaningful transaminase increases — notable blood chemistry outcomes.
- Medium- and long-chain triacylglycerols in postoperative patients: structured lipids versus a physical mixture
PubMed ID: 10319358
Structured vs physical lipid emulsions gave different AST/ALT and triglyceride patterns — clear blood chemistry differences.
- Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group
PubMed ID: 10051494
Lamivudine markedly improved virological and biochemical (ALT) responses in HBV — direct blood chemistry improvements.
- Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease
PubMed ID: 10533795
Long‑term UDCA modestly improved transaminases in chronic HCV — measurable biochemical benefit.
- A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis
PubMed ID: 14687046
UDCA superior to SAMe in lowering bile acids and AST/ALT in intrahepatic cholestasis — strong blood-chemistry improvement.
- A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia
PubMed ID: 15639688
Ezetimibe/simvastatin markedly lowered LDL with uncommon liver enzyme elevations — major blood-chemistry outcome.
- Effect of Hejie decoction on T cell immune state of chronic hepatitis B patients
PubMed ID: 15133849
Hepatitis B trial reported reductions in ALT/AST and bilirubin alongside immune changes.
- Metformin in the treatment of patients with non-alcoholic steatohepatitis
PubMed ID: 14987322
Metformin + diet improved insulin resistance and transaminases — beneficial blood-chemistry changes.
- A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease
PubMed ID: 15842582
Metformin improved ALT normalization and liver histology in NAFLD — clear blood-chemistry benefit.
- Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)
PubMed ID: 15695129
Large RCT: simvastatin+fenofibrate produced clear improvements in triglycerides/LDL/HDL—strong blood‑chemistry benefit.
- Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia
PubMed ID: 16260426
Red yeast rice trial showed marked LDL/total cholesterol/triglyceride reductions—lipid/blood chemistry improvement.
- The efficacy of Liv-52 on liver cirrhotic patients: a randomized, double-blind, placebo-controlled first approach
PubMed ID: 16194047
Liv‑52 improved ALT/AST and clinical liver scores—hepatochemical improvement.
- Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study
PubMed ID: 15864235
Ezetimibe/simvastatin lowered LDL‑C substantially vs atorvastatin—direct, large effect on blood lipids.
- Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia
PubMed ID: 16630994
Fenofibrate+ezetimibe extension study showed larger LDL reductions—relevant to sustained blood‑chemistry control.
- Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children
PubMed ID: 18330955
Lifestyle intervention produced meaningful ALT/AST and BMI improvements in NAFLD children — clear blood chemistry effects (indirect for aspartate).
- A new way: alleviating postembolization syndrome following transcatheter arterial chemoembolization
PubMed ID: 19216654
Combined dexamethasone + ginsenosides significantly reduced AST/ALT after TACE — notable liver enzyme improvement (intervention unrelated to aspartate).
- Iron depletion before HCV antiviral therapy: a pilot, randomized, controlled trial
PubMed ID: 19760753
Phlebotomy clearly reduced AST/ALT and ferritin before HCV therapy—direct biochemical impact on blood markers (mechanistically unrelated to aspartate).
- Hepatocellular integrity after parenteral nutrition: comparison of a fish-oil-containing lipid emulsion with an olive-soybean oil-based lipid emulsion
PubMed ID: 19916246
Randomized trial (SMOFlipid) produced clear, quantitatively significant reductions in AST/ALT/alpha‑GST — strong blood‑chemistry signal (but for a lipid emulsion, not aspartate).
- Efficacy and safety of intravenous stronger neo-minophagen C and S-adenosyl-L-methionine in treatment of pregnant woman with chronic hepatitis B: a pilot study
PubMed ID: 20671623
SNMC markedly improved ALT/AST in pregnant HBV patients — strong liver enzyme improvement signal (not related to aspartate supplement).
- Enteral nutrition is superior to total parenteral nutrition for pancreatic cancer patients who underwent pancreaticoduodenectomy
PubMed ID: 21669582
Enteral feeding after pancreatic surgery produced better AST/ALT and total protein—clear improvement in blood chemistry markers.
- A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis
PubMed ID: 22006541
GS‑9450 produced dose‑dependent large ALT reductions in NASH patients—strong blood chemistry effect.
- Pattern of liver enzyme elevations in acute ST-elevation myocardial infarction
PubMed ID: 22113063
Large STEMI cohort showing AST/ALT commonly elevated and correlated with worse outcomes — direct measurement of blood-chemistry markers.
- Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial
PubMed ID: 23234816
Chlorella adjunct lowered ALT/AST and multiple metabolic blood markers over 3 months — robust blood-chemistry improvement.
- Effect of parenteral fish oil lipid emulsion in parenteral nutrition supplementation combined with enteral nutrition support in patients undergoing pancreaticoduodenectomy
PubMed ID: 22699972
Parenteral fish-oil improved ALT/AST and clinical outcomes post-pancreatic surgery — clear blood-chemistry improvements.
- Antifibrotic effect of aloe vera in viral infection-induced hepatic periportal fibrosis
PubMed ID: 22563189
Aloe fractions reduced transaminases and fibrosis biomarkers — direct improvement in blood-based liver markers.
- Long-term effects of aerobic plus resistance training on the adipokines and neuropeptides in nonalcoholic fatty liver disease obese adolescents
PubMed ID: 22932160
Resistance training added to aerobic exercise improved ALT and insulin/HOMA-IR — meaningful blood-chemistry changes.
- Improvement of liver function in humans using a mixture of schisandra fruit extract and sesamin
PubMed ID: 22610748
Schisandra+sesamin decreased ALT/AST and increased antioxidant markers over months — direct blood-chemistry benefit.
- The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers
PubMed ID: 22739141
Therapeutic heparins caused frequent, large transient ALT/AST rises with hepatic microRNA changes — strong blood-chemistry safety signal.
- Regulatory T-cell responses in chronic hepatitis B patients treated with nucleos(t)ide analogs compared with healthy subjects and untreated infected individuals
PubMed ID: 22626879
Antiviral therapy in chronic HBV lowered HBV DNA and ALT/AST over 96 weeks — clinically relevant blood-chemistry improvements.
- [Ornithine aspartate and naloxone combined therapy for hepatic encephalopathy affects cognitive function, prognosis, and neuropeptide levels]
PubMed ID: 24025143
Ornithine‑aspartate + naloxone improved ALT/GGT/bilirubin in hepatic encephalopathy — direct blood‑chemistry improvements from an aspartate-containing agent.
- Sulforaphane-rich broccoli sprout extract improves hepatic abnormalities in male subjects
PubMed ID: 26604653
Sulforaphane extract reduced ALT and γ‑GTP and an oxidative marker — clear improvements in blood/liver chemistry markers.
- Ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial
PubMed ID: 26502869
UDCA and SAMe meaningfully reduced total bile acids and ALT/AST in cholestasis of pregnancy — direct blood‑chemistry improvements.
- Effect of canagliflozin on liver function tests in patients with type 2 diabetes
PubMed ID: 26575250
Canagliflozin consistently lowered liver enzymes (ALT/AST/GGT) linked to metabolic improvements — strong blood‑chemistry impact (drug effect).
- Long-Term Treatment with n-3 Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver Disease
PubMed ID: 26316434
n‑3 PUFA improved ALT/AST, insulin resistance and lipid profile in pediatric NAFLD — notable positive blood‑chemistry changes.
- Effects of Histidine Supplementation on Global Serum and Urine (1)H NMR-based Metabolomics and Serum Amino Acid Profiles in Obese Women from a Randomized Controlled Study
PubMed ID: 28447460
Study reported decreases in cholesterol/triglycerides and glucose‑related metabolites alongside increased serum aspartate after histidine supplementation — suggests potential blood‑chemistry benefits associated with higher aspartate.
- High Dose of Silymarin in Patients with Decompensated Liver Disease: A Randomized Controlled Trial
PubMed ID: 29135373
High‑dose silymarin significantly decreased ALT/AST and improved Child score in decompensated cirrhosis — clear blood chemistry/liver enzyme changes (not aspartate supplementation).
- Four-oil intravenous lipid emulsion effect on plasma fatty acid composition, inflammatory markers and clinical outcomes in acutely ill patients: A randomised control trial (Foil fact)
PubMed ID: 30638739
SMOFlipid increased EPA/DHA and showed larger short‑term decreases in liver enzymes versus soybean oil—improves blood lipid/factory markers.
- The effects of two mixed intravenous lipid emulsions on clinical outcomes in infants after gastrointestinal surgery: a prospective, randomized study
PubMed ID: 30474700
SMOF lipid in infants associated with lower ALT/AST/DB after long‑term PN—improved hepatic blood chemistry.
- Gut Permeability Might be Improved by Dietary Fiber in Individuals with Nonalcoholic Fatty Liver Disease (NAFLD) Undergoing Weight Reduction
PubMed ID: 30453660
Increased dietary fiber improved zonulin and reduced ALT/AST and steatosis—beneficial blood/liver chemistry.
- Prevalence of responders for hepatic fat, adiposity and liver enzyme levels in response to a lifestyle intervention in children with overweight/obesity: EFIGRO randomized controlled trial
PubMed ID: 31778277
Lifestyle+exercise improved liver fat and GGT responders vs control—beneficial blood/liver markers.
- Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial
PubMed ID: 30920975
Silymarin/pioglitazone/vitamin E groups decreased liver enzymes and improved anthropometrics—blood chemistry improvements documented.
- Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial
PubMed ID: 31345778
NorUDCA produced a robust ~28% ALT reduction in NAFLD—strong direct improvement in liver chemistry.
- Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis
PubMed ID: 38729399
Cotadutide phase‑2 trial produced substantial reductions in liver fat and ALT/AST — robust effect on blood chemistry biomarkers.
- [Magnesium, calcium, hemoglobin, hematocrit, estriol and human placental lactogen with magnesium substitution in pregnancy]
PubMed ID: 2210311
Large pregnancy trial of magnesium-aspartate reduced maternal/neonatal complications and showed some hormonal differences—consistent with clinically meaningful systemic effects of Mg-aspartate.
- Oral magnesium supplementation as prophylaxis for noise-induced hearing loss: results of a double blind field study
PubMed ID: 8460390
Large field RCT showed magnesium-aspartate increased lymphocyte Mg and serum/erythrocyte Mg and reduced permanent hearing loss — clear systemic magnesium effects.
- [Potassium substitution during coronary surgery: K(+)-Mg+(+)-aspartate-complex (Inzolen) versus potassium chloride]
PubMed ID: 8297448
Potassium‑magnesium‑aspartate raised serum magnesium markedly at declamping (1.48 → 2.33 mmol/L) — strong intraoperative blood-chemistry effect.
- Nutritional dose of magnesium in hypertensive patients on beta blockers lowers systolic blood pressure: a double-blind, cross-over study
PubMed ID: 7913949
Oral magnesium‑aspartate increased serum/urine magnesium and modestly lowered systolic BP in hypertensives.
- Reduction of blood pressure with oral magnesium supplementation in women with mild to moderate hypertension
PubMed ID: 8017327
Six months of Mg‑L‑aspartate increased urinary magnesium and significantly lowered diastolic BP — direct blood/chemistry effects.
- [Effectiveness of oral versus parenteral iron substitution in autologous blood donors]
PubMed ID: 7950288
Direct: trial used oral Fe2+ aspartate and measured hemoglobin, ferritin, and reticulocyte responses—clear impact on blood chemistry (iron indices).
- Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study
PubMed ID: 9185752
OA substantially lowered fasting/postprandial venous ammonia (clear blood chemistry improvement in cirrhosis).
- Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study
PubMed ID: 9625322
Shows statistically significant reductions in venous ammonia (a blood chemical relevant to hepatic/metabolic health).
- Dose-dependent hormonal effects of toremifene in postmenopausal breast cancer patients
PubMed ID: 10803924
Toremifene trial explicitly measured ASAT (aspartate aminotransferase) and found no increase — direct blood chemistry measurement involving an aspartate enzyme.
- [Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy]
PubMed ID: 15958319
LOLA reduced serum ammonia and improved liver biochemistry in cirrhosis.
- Effect of cold blood cardioplegia enriched with potassium-magnesium aspartate during coronary artery bypass grafting
PubMed ID: 17043614
Potassium‑Mg aspartate cardioplegia decreased cardiac troponin I rises and early AF — direct impact on perioperative biochemical markers.
- [Clinical investigation of the protective effects of potassium magnesium aspartate against arrhythmia and its possible anti-oxidative mechanism]
PubMed ID: 17996133
Potassium‑magnesium‑aspartate in coronary disease patients produced large improvements in oxidative stress biomarkers (GSH/GSSG, MDA, ox‑LDL) and markedly reduced premature beats—strong clinical signal for beneficial effects on blood/oxidative chemistry in that population.
- Comparison of blood tests for liver fibrosis specific or not to NAFLD
PubMed ID: 18977552
FibroMeter uses AST within a validated panel to stage NAFLD—strong clinical relevance of aspartate‑related blood chemistry for liver disease.
- L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy
PubMed ID: 18983791
L‑ornithine‑L‑aspartate produced significant reductions in blood ammonia (a key pathological biochemical) in cirrhotic patients — direct support for improved blood chemistry in that context.
- Perioperative indocyanine green clearance is predictive for prolonged intensive care unit stay after coronary artery bypass grafting--an observational study
PubMed ID: 19747406
Study linked postoperative ICG clearance and elevated ASAT (AST) to prolonged ICU stay — directly concerns blood chemistry (AST) and clinical outcomes.
- Diagnosis of advanced fibrosis in HIV and hepatitis C virus-coinfected patients via a new noninvasive index: the HGM-3 index
PubMed ID: 19686437
HGM‑3 index (including AST-based comparators) accurately identified advanced fibrosis — demonstrates importance of AST/serum indices in blood chemistry diagnostics (indirect to aspartate supplementation).
- A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy
PubMed ID: 21646910
LOLA led to significant reductions in arterial ammonia and improved encephalopathy—direct, clinically meaningful changes in blood biochemistry (ammonia) in liver disease, supporting aspartate's role in healthy blood chemistry in that context.
- Oral magnesium supplementation reduces insulin resistance in non-diabetic subjects - a double-blind, placebo-controlled, randomized trial
PubMed ID: 21205110
Mg‑aspartate RCT improved fasting glucose and insulin sensitivity—clear blood chemistry benefit.
- [The role of magnesium in the implementation of vascular reactions during anesthesia in cardiac surgery patients]
PubMed ID: 21853612
In cardiac surgery patients, potassium/magnesium asparginate infusion preserved normal magnesium concentrations, reduced hypertension episodes and improved peripheral microcirculation — direct evidence that an aspartate salt supports perioperative electrolyte/vascular balance.
- Effect of astaxanthin supplementation on muscle damage and oxidative stress markers in elite young soccer players
PubMed ID: 22828460
Astaxanthin reduced post‑exercise CK and AST rises (improved circulating enzyme profile after exercise).
- Efficacy and safety of ferrous asparto glycinate in the management of iron deficiency anaemia in pregnant women
PubMed ID: 24959663
Ferrous asparto glycinate produced significantly greater increases in hemoglobin and ferritin over 28 days versus ferrous ascorbate in pregnant women (direct human evidence).
- L-ornithine L-aspartate in bouts of overt hepatic encephalopathy
PubMed ID: 28749571
LOLA significantly lowered venous ammonia and reduced hospital stay in overt hepatic encephalopathy — direct effect on a key blood chemistry parameter (ammonia).
- Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo
PubMed ID: 29727385
LOLA produced a robust reduction in arterial ammonia and improved laboratory/clinical markers in cirrhosis, directly supporting improvements in blood chemistry related to ammonia toxicity.
- 1,5-Anhydroglucitol predicts CKD progression in macroalbuminuric diabetic kidney disease: results from non-targeted metabolomics
PubMed ID: 30830377
Circulating L‑aspartic acid inversely associated with progression to dialysis/creatinine doubling/death in diabetic macroalbuminuria—direct biomarker evidence linking aspartate levels to clinically important blood/renal chemistry outcomes.
- Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding
PubMed ID: 30079329
LOLA reduced overt hepatic encephalopathy and changed liver‑related outcomes in an RCT, supporting beneficial effects on liver‑related blood chemistry and ammonia handling from an aspartate‑containing product.
- L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial
PubMed ID: 34822189
LOLA significantly lowered ammonia and improved liver‑related labs and outcomes — clear effect on clinically relevant blood chemistry.
- Peripheral blood indices to predict PFS/OS with anlotinib as a subsequent treatment in advanced small-cell lung cancer
PubMed ID: 34302324
Baseline AST (aspartate aminotransferase) independently predicted PFS/OS in SCLC — shows clinical significance of AST as a blood chemistry marker.
- Telemonitoring-Supported Exercise Training in Employees With Metabolic Syndrome Improves Liver Inflammation and Fibrosis
PubMed ID: 34140456
Large telemonitored exercise RCT produced significant decreases in AST/ALT and fibrosis indices — direct evidence of interventions changing AST (aspartate aminotransferase).
- Machine learning algorithm outperforms fibrosis markers in predicting significant fibrosis in biopsy-confirmed NAFLD
PubMed ID: 33908180
Machine‑learning NAFLD model relied heavily on AST to predict fibrosis (AUROC 0.902), underscoring AST's importance in blood chemistry profiling.
- The potential hepatoprotective effect of metformin in hepatitis C virus-infected adolescent patients with beta thalassemia major: Randomised clinical trial
PubMed ID: 33617679
Metformin RCT significantly lowered AST and improved antioxidant/fibrosis markers — direct AST (aspartate aminotransferase) change demonstrating blood‑chemistry impact.
- Intravenous versus oral 'L-ornithine-L-aspartate' in overt hepatic encephalopathy: a randomized comparative study
PubMed ID: 38789596
LOLA produced robust, clinically meaningful reductions in serum ammonia and improved encephalopathy—direct improvement in a blood chemistry parameter tied to nitrogen metabolism.
- Machine learning and data-driven inverse modeling of metabolomics unveil key processes of active aging
PubMed ID: 40993122
Metabolomics identified plasma aspartate as a dominant biomarker associated with active phenotype and AST/ALT variability — strong blood chemistry relevance.
Metabolism (59)
- Metformin in the treatment of patients with non-alcoholic steatohepatitis
PubMed ID: 14987322
Metformin + diet improved insulin resistance and transaminases — direct metabolic endpoints.
- A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia
PubMed ID: 15639688
Ezetimibe/simvastatin lowered LDL substantially — relevant to metabolic/blood-chemistry health.
- Efficacy and safety of 300 micrograms and 400 micrograms cerivastatin once daily in patients with primary hypercholesterolaemia: a multicentre, randomized, double-blind, placebo-controlled study
PubMed ID: 10505301
Cerivastatin caused marked LDL‑C lowering — clear metabolic/lipid effect.
- Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia
PubMed ID: 9761083
Extended‑release niacin produced clear, clinically relevant lipid changes — strong metabolic relevance (but drug‑specific).
- Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients
PubMed ID: 9737807
Troglitazone significantly improved fasting glucose and insulin sensitivity — direct metabolic outcomes.
- Long-term metabolic effects of n-3 polyunsaturated fatty acids in patients with coronary artery disease
PubMed ID: 7702027
High‑dose fish oil produced a clear 19% triglyceride reduction — direct metabolic effect.
- Serum metabolomic profiling reveals potential biomarkers in assessing the management of women with polycystic ovary syndrome: a randomized controlled trial
PubMed ID: 34873082
Metabolomic profiling in treated PCOS showed aspartic acid rises — direct measurement linking aspartate to metabolic changes in a metabolic/endocrine condition.
- Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes and Acarbose Research Group
PubMed ID: 9347244
Acarbose added to sulfonylurea significantly lowered HbA1c — direct metabolic glycemic benefit.
- Machine learning and data-driven inverse modeling of metabolomics unveil key processes of active aging
PubMed ID: 40993122
Metabolomics links higher plasma aspartate to a metabolic network associated with better physical performance — strong metabolic association.
- Intravenous versus oral 'L-ornithine-L-aspartate' in overt hepatic encephalopathy: a randomized comparative study
PubMed ID: 38789596
L‑ornithine‑L‑aspartate (LOLA) markedly reduced serum ammonia in hepatic encephalopathy, showing a clear metabolic (nitrogen/ammonia) effect directly involving aspartate.
- Development and Pragmatic Randomized Controlled Trial of Healthy Ketogenic Diet Versus Energy-Restricted Diet on Weight Loss in Adults with Obesity
PubMed ID: 39771001
Randomized diet trial showed clear metabolic improvements (weight, HbA1c, lipids); relevant to 'supports metabolism' but unrelated to aspartate supplement.
- L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial
PubMed ID: 34822189
LOLA markedly lowered blood ammonia and improved HE outcomes — directly relevant to hepatic nitrogen metabolism.
- 1,5-Anhydroglucitol predicts CKD progression in macroalbuminuric diabetic kidney disease: results from non-targeted metabolomics
PubMed ID: 30830377
Lower plasma L‑aspartic acid was associated with higher risk of kidney disease progression in diabetic macroalbuminuria, implicating aspartate metabolism in clinical metabolic outcomes.
- Efficacy and safety of ferrous asparto glycinate in the management of iron deficiency anaemia in pregnant women
PubMed ID: 24959663
Ferrous asparto glycinate improved iron indices (Hb, ferritin) indicating altered iron metabolism/uptake vs comparator.
- Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial
PubMed ID: 25038208
LOLA (an aspartate‑containing prep) is used to enhance ammonia detoxification and amino‑acid related metabolic pathways in cirrhosis.
- Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy
PubMed ID: 22078345
L‑ornithine‑L‑aspartate (an aspartate‑containing drug) produced clinically meaningful improvements in hepatic encephalopathy and reduced hospital stay by facilitating ammonia detoxification — a clear metabolic/detox effect.
- Oral magnesium supplementation reduces insulin resistance in non-diabetic subjects - a double-blind, placebo-controlled, randomized trial
PubMed ID: 21205110
6‑month RCT: oral magnesium‑aspartate improved fasting glucose and insulin sensitivity in overweight non‑diabetic subjects.
- A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy
PubMed ID: 21646910
LOLA (L‑ornithine L‑aspartate) significantly lowered arterial ammonia and improved MHE—direct metabolic detoxification of ammonia supports metabolism in cirrhosis.
- L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy
PubMed ID: 18983791
L‑ornithine‑L‑aspartate robustly lowered blood ammonia (improved ammonia metabolism) in cirrhotic patients — direct metabolic detoxification evidence.
- Effect of cold blood cardioplegia enriched with potassium-magnesium aspartate during coronary artery bypass grafting
PubMed ID: 17043614
Potassium‑Mg aspartate improved myocardial protection and biochemical markers during surgery.
- [Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy]
PubMed ID: 15958319
IV LOLA lowered blood ammonia and improved hepatic function — direct metabolic effect.
- A controlled, randomized, double-blind trial of prophylaxis against jaundice among breastfed newborns
PubMed ID: 16061593
Oral L‑aspartic acid in newborns increased fecal bilirubin excretion and reduced serum bilirubin — indicates hepatic/metabolic processing effects.
- Effect of multivitamin supplementation on the homocysteine and methylmalonic acid blood concentrations in women over the age of 60 years
PubMed ID: 15309436
Six‑month multivitamin supplementation produced clear biochemical metabolic changes (lowered homocysteine/MMA) — direct metabolic relevance (not aspartate but metabolic context).
- Effects of medium-chain and long-chain triacylglycerols in pediatric surgical patients
PubMed ID: 10869893
TPN composition changed metabolic outcomes (nitrogen balance, ketogenesis, AST/bilirubin trends) in surgical patients.
- Can one really measure magnesium deficiency using the short-term magnesium loading test?
PubMed ID: 10583708
Mg-aspartate therapy measurably altered magnesium retention and bone Mg (metabolic mineral effects); magnesium is central to many metabolic pathways.
- Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study
PubMed ID: 9625322
L-ornithine–L-aspartate lowered fasting/postprandial ammonia (supports hepatic nitrogen/urea metabolism).
- Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study
PubMed ID: 9185752
L‑ornithine‑L‑aspartate substantially lowered ammonia (key metabolic detoxification) in cirrhosis.
- Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer
PubMed ID: 9816275
PALA is N-(phosphonacetyl)-L-aspartate (an aspartate analog) and produced dose‑dependent inhibition of ATCase — direct, strong metabolic/biochemical relevance.
- Amino acid-enriched glucose-insulin-potassium infusion improves hemodynamic function after coronary bypass surgery. A double-blind study in patients with unstable angina and/or compromised left ventricular function
PubMed ID: 7787408
Amino-acid–enriched GIK including aspartate produced marked improvements in cardiac performance and ventricular work—relevant to metabolic/energetic function in surgical patients.
- Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis
PubMed ID: 38729399
Cotadutide significantly reduced hepatic fat and transaminases in MASH — robust metabolic benefit (drug intervention).
- The effect of ertugliflozin in patients with nonalcoholic fatty liver disease associated with type 2 diabetes mellitus: A randomized controlled trial
PubMed ID: 39533572
Ertugliflozin produced marked weight loss, liver enzyme and liver‑fat improvements — strong metabolic effect (not aspartate supplementation).
- Comparison of the efficacy of pioglitazone and metformin on ultrasound grade and liver enzymes level in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial
PubMed ID: 36791804
Metformin/pioglitazone + vitamin E improved hepatic steatosis and liver enzymes—metabolic improvement in NAFLD.
- Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial
PubMed ID: 36797481
Tropifexor markedly reduced liver fat (MRI‑PDFF) and ALT in NASH—strong metabolic/liver effect.
- Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2)
PubMed ID: 36855099
Tafolecimab produced large LDL‑C reductions—direct lipid‑metabolic benefit.
- Effects of Clostridium butyricum Capsules Combined with Rosuvastatin on Intestinal Flora, Lipid Metabolism, Liver Function and Inflammation in NAFLD Patients
PubMed ID: 35869734
Probiotic + rosuvastatin reduced lipids, liver enzymes and fibrosis markers—clear metabolic effects.
- Effects of Shenxiang Suhe Pill on coronary heart disease complicated with nonalcoholic fatty liver disease: A case-control study
PubMed ID: 36626456
Shenxiang Suhe improved CAP (liver fat), hs‑CRP and HDL in NAFLD—metabolic outcomes.
- Danshao Shugan Granule therapy for non-alcoholic fatty liver disease
PubMed ID: 35999630
Herbal TCM (Danshao Shugan) produced large ALT/AST and lipid improvements in NAFLD—metabolic relevance.
- Effects of sitagliptin on intrahepatic lipid content in patients with non-alcoholic fatty liver disease
PubMed ID: 36072931
T2DM patients saw HbA1c and intrahepatic lipid improvements—direct metabolic benefits.
- Spirulina supplementation during gradual weight loss in competitive wrestlers
PubMed ID: 33715648
Spirulina reduced body fat and some metabolic markers during weight loss—metabolic relevance.
- Vitamin D and nonalcoholic fatty liver disease in children: a randomized controlled clinical trial
PubMed ID: 34459959
Vitamin D in pediatric NAFLD reduced liver fat and improved multiple metabolic markers (HOMA‑IR, lipids).
- Whole-grain consumption and its effects on hepatic steatosis and liver enzymes in patients with non-alcoholic fatty liver disease: a randomised controlled clinical trial
PubMed ID: 31685037
Increased whole‑grain intake improved hepatic steatosis and reduced ALT/AST—dietary metabolic improvement.
- Pinitol consumption improves liver health status by reducing oxidative stress and fatty acid accumulation in subjects with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial
PubMed ID: 31030165
Pinitol reduced liver fat, liver enzymes and oxidative stress in NAFLD—strong metabolic endpoints.
- Standardized Nigella sativa seed oil ameliorates hepatic steatosis, aminotransferase and lipid levels in non-alcoholic fatty liver disease: A randomized, double-blind and placebo-controlled clinical trial
PubMed ID: 30639231
Nigella sativa seed oil reduced hepatic steatosis and ALT in NAFLD—direct metabolic/liver effects.
- Prevalence of responders for hepatic fat, adiposity and liver enzyme levels in response to a lifestyle intervention in children with overweight/obesity: EFIGRO randomized controlled trial
PubMed ID: 31778277
Intensive lifestyle+exercise in children improved liver fat, BMI/adiposity and GGT—clear metabolic benefit.
- A Randomized Controlled Trial of a Herbal Compound for Improving Metabolic Parameters in Diabetic Patients with Uncontrolled Dyslipidemia
PubMed ID: 30727929
Multiherbal add‑on to statin therapy lowered lipids and HbA1c—metabolic/lipid‑glucose effects.
- Dietary chlorogenic acid regulates gut microbiota, serum-free amino acids and colonic serotonin levels in growing pigs
PubMed ID: 29141471
Pig study showed increased serum free aspartic acid and altered gut/5‑HT — direct change in aspartate biology (animal model), moderate relevance to metabolic effects.
- Effects of Histidine Supplementation on Global Serum and Urine (1)H NMR-based Metabolomics and Serum Amino Acid Profiles in Obese Women from a Randomized Controlled Study
PubMed ID: 28447460
Directly relevant: histidine supplementation increased serum aspartate and produced improvements in lipid and glucose‑related metabolites in obese/metabolic‑syndrome subjects, implying a metabolic effect linked to raised aspartate.
- Long-Term Treatment with n-3 Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver Disease
PubMed ID: 26316434
n‑3 PUFA improved insulin resistance, triglycerides/HDL and steatosis in pediatric NAFLD — substantive metabolic benefit.
- Capsaicin-containing chili improved postprandial hyperglycemia, hyperinsulinemia, and fasting lipid disorders in women with gestational diabetes mellitus and lowered the incidence of large-for-gestational-age newborns
PubMed ID: 25771490
Low‑dose capsaicin improved postprandial glucose/insulin and lipids in gestational diabetes — direct metabolic improvements.
- Effect of canagliflozin on liver function tests in patients with type 2 diabetes
PubMed ID: 26575250
Canagliflozin produced consistent, clinically relevant improvements in glycemic control, weight and lowered liver enzymes — strong metabolic effect (but drug, not aspartate).
- Weight reduction improves markers of hepatic function and insulin resistance in type-2 diabetic patients with non-alcoholic fatty liver
PubMed ID: 24250305
Diet and exercise–induced ~15% weight loss produced marked improvements in insulin resistance and liver enzymes—strong metabolic signal; unrelated to aspartate supplementation.
- Low-dose pioglitazone, flutamide, metformin plus an estro-progestagen for non-obese young women with polycystic ovary syndrome: increasing efficacy and persistent safety over 30 months
PubMed ID: 20500100
Intervention produced marked insulin‑sensitivity improvements and visceral fat reduction — clear metabolic signal (not aspartate).
- Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis
PubMed ID: 19248193
Telmisartan improved insulin resistance and liver histology in NASH — clear metabolic effects.
- Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study
PubMed ID: 18640473
Metformin + lifestyle improved metabolic endpoints and liver markers in NAFLD.
- Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia
PubMed ID: 16630994
Fenofibrate+ezetimibe produced larger LDL reductions—relevant to metabolic lipid control.
- Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia
PubMed ID: 16260426
Red yeast rice produced meaningful LDL/total cholesterol/triglyceride reductions—metabolic lipid benefit.
- Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)
PubMed ID: 15695129
Simvastatin+fenofibrate produced substantial improvements in triglycerides/LDL/HDL—clear metabolic effect.
- A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease
PubMed ID: 15842582
Metformin improved liver fat, ALT and histology in NAFLD — strong metabolic benefit.
- Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes
PubMed ID: 16002175
Large diabetes drug tolerability trial documented differing metabolic effects (weight, enzymes) across drugs.
Detoxification (36)
- A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse
PubMed ID: 11093966
Naltrexone reduced alcohol use and GGT in compliant subjects — supports reduction of alcohol‑related hepatic toxin burden.
- Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial
PubMed ID: 25038208
LOLA is used to enhance hepatic ammonia detoxification and improved cognitive outcomes in cirrhosis patients.
- Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy
PubMed ID: 22078345
L‑ornithine‑L‑aspartate (LOLA) clearly improved hepatic encephalopathy clinical outcomes and shortened hospital stay by promoting ammonia detoxification — direct evidence for detox support by an aspartate‑containing therapy.
- The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition
PubMed ID: 21339541
L‑ornithine‑L‑aspartate (LOLA) is used for ammonia detoxification in hepatic encephalopathy and improved CFF in cirrhotics—direct evidence of detox support context.
- A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy
PubMed ID: 21646910
L‑ornithine L‑aspartate (LOLA) robustly lowered arterial ammonia and improved minimal hepatic encephalopathy—direct, high-quality evidence that aspartate (as part of LOLA) supports hepatic detox (ammonia) processes.
- L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy
PubMed ID: 18983791
Strong clinical evidence: IV L‑ornithine‑L‑aspartate significantly reduced postprandial blood ammonia and improved encephalopathy grade in cirrhotic patients — direct detoxification effect.
- [Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy]
PubMed ID: 15958319
IV LOLA infusion markedly decreased blood ammonia and improved liver function in cirrhotics.
- A controlled, randomized, double-blind trial of prophylaxis against jaundice among breastfed newborns
PubMed ID: 16061593
Direct oral L‑aspartic acid in neonates reduced serum bilirubin (≈24% reduction vs control) and increased fecal bilirubin excretion — clear evidence of enhanced bilirubin clearance/detoxification in this population.
- Neuroprotective effects of glycine for therapy of acute ischaemic stroke
PubMed ID: 10629347
Oral glycine lowered CSF aspartate/glutamate and was associated with better stroke outcomes — direct evidence of lowering excitotoxic amino acids (detoxifying effect in CNS).
- Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study
PubMed ID: 9625322
Direct evidence: L-ornithine–L-aspartate significantly lowered fasting and postprandial venous ammonia, improving hepatic encephalopathy—strong detox/ammonia‑clearance effect.
- Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study
PubMed ID: 9185752
L‑ornithine‑L‑aspartate markedly lowered fasting/postprandial ammonia in cirrhotic encephalopathy — direct detoxification evidence.
- Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study
PubMed ID: 34847228
Deferiprone is an iron chelator that directly reduces liver iron concentration—clear detox/chelation process.
- Vitamin D and nonalcoholic fatty liver disease in children: a randomized controlled clinical trial
PubMed ID: 34459959
Vitamin D improved liver steatosis and enzymes in pediatric NAFLD—relevant to liver clearance/metabolic health.
- Fucoidan and Fucoxanthin Attenuate Hepatic Steatosis and Inflammation of NAFLD through Modulation of Leptin/Adiponectin Axis
PubMed ID: 33809062
Fucoidan+fucoxanthin reduced liver enzymes and liver fat in NAFLD—relevant to hepatic 'detox' and liver health.
- Assessment of Renal and Hepatic Tissue-Protective Effects of N-Acetylcysteine via Ammonia Metabolism: A Prospective Randomized Study
PubMed ID: 29540661
NAC lowered blood ammonia and BUN post‑CABG, directly relevant to metabolic detox/nitrogen clearance.
- Sulforaphane-rich broccoli sprout extract improves hepatic abnormalities in male subjects
PubMed ID: 26604653
Sulforaphane‑rich broccoli sprout extract lowered ALT/γ‑GTP and urinary 8‑OHdG (oxidative DNA damage), consistent with enhanced detox/antioxidant effects.
- [Ornithine aspartate and naloxone combined therapy for hepatic encephalopathy affects cognitive function, prognosis, and neuropeptide levels]
PubMed ID: 24025143
Ornithine-aspartate significantly lowered blood ammonia and improved encephalopathy outcomes — strong evidence for hepatic detox (ammonia) in patients.
- Improvement of liver function in humans using a mixture of schisandra fruit extract and sesamin
PubMed ID: 22610748
Schisandra + sesamin reduced ALT/AST and increased antioxidant capacity — supports liver detox/antioxidant pathways.
- Antifibrotic effect of aloe vera in viral infection-induced hepatic periportal fibrosis
PubMed ID: 22563189
Oral aloe fractions reduced liver enzymes and fibrosis biomarkers in periportal fibrosis patients — supports hepatic repair/detox surrogate endpoints.
- Effect of parenteral fish oil lipid emulsion in parenteral nutrition supplementation combined with enteral nutrition support in patients undergoing pancreaticoduodenectomy
PubMed ID: 22699972
Parenteral fish-oil after surgery improved liver tests (detox function surrogate) and reduced complications — relevant to hepatic recovery/detox.
- Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial
PubMed ID: 23234816
Chlorella adjunct reduced transaminases and metabolic markers in NAFLD patients — moderate direct signal for hepatic detox/clearing improvement.
- Efficacy and safety of intravenous stronger neo-minophagen C and S-adenosyl-L-methionine in treatment of pregnant woman with chronic hepatitis B: a pilot study
PubMed ID: 20671623
SNMC rapidly normalized ALT/AST in pregnant HBV — indicates improved hepatic handling/detox markers (but not aspartate‑specific).
- Hepatocellular integrity after parenteral nutrition: comparison of a fish-oil-containing lipid emulsion with an olive-soybean oil-based lipid emulsion
PubMed ID: 19916246
Clear reductions in hepatocellular markers (AST/alpha‑GST) suggest improved hepatic handling/detox after SMOFlipid use.
- Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study
PubMed ID: 17393330
Trial showed decreased fasting ammonia with probiotic+FOS in cirrhotics—directly relevant to nitrogen detoxification.
- The efficacy of Liv-52 on liver cirrhotic patients: a randomized, double-blind, placebo-controlled first approach
PubMed ID: 16194047
Herbal product Liv‑52 decreased ALT/AST and improved clinical liver scores in cirrhosis—hepatoprotective/detox relevance.
- Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy
PubMed ID: 16143129
UDCA markedly improved liver tests in cholestasis of pregnancy—direct liver detox/process support.
- Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease
PubMed ID: 10533795
UDCA modestly improved liver enzymes in chronic HCV — beneficial hepatic biochemical effect.
- Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients
PubMed ID: 10524635
Glycyrrhizin ± ursodeoxycholic acid reduced liver enzymes significantly — indicates improved hepatic detox/biochemical profile.
- Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial. Spanish Group for the Study of Alcoholic Fatty Liver
PubMed ID: 9537864
Metadoxine accelerated normalization of aminotransferases and reduced steatosis in alcoholic patients — direct hepatic 'detox' effect.
- Effect of ursodeoxycholic acid on hypertransaminasaemia and bile acid composition in patients undergoing bone marrow transplantation--a double-blind randomized control study
PubMed ID: 8842833
Ursodeoxycholic acid accelerated normalization of liver enzymes after bone marrow transplant — supports hepatic recovery/detoxification processes.
- Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo
PubMed ID: 29727385
L‑ornithine L‑aspartate definitively reduced arterial ammonia, lowered recurrence of overt hepatic encephalopathy and improved ammonia-related outcomes—strong evidence for ammonia detoxification in liver disease.
- Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding
PubMed ID: 30079329
Randomized trial: L‑ornithine‑L‑aspartate significantly reduced incidence and severity of overt hepatic encephalopathy in cirrhotic patients—strong clinical evidence for ammonia detoxification benefit from an aspartate‑containing therapy.
- L-ornithine L-aspartate in bouts of overt hepatic encephalopathy
PubMed ID: 28749571
Direct RCT evidence: IV L‑ornithine L‑aspartate reduced venous ammonia and improved recovery/encephalopathy in cirrhotic patients — strong, direct evidence for ammonia detoxification by an aspartate‑containing therapy.
- L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial
PubMed ID: 34822189
L‑ornithine L‑aspartate (LOLA) directly lowered blood ammonia and improved hepatic encephalopathy and mortality — strong evidence for detoxifying (ammonia) activity.
- Intravenous versus oral 'L-ornithine-L-aspartate' in overt hepatic encephalopathy: a randomized comparative study
PubMed ID: 38789596
Strong direct evidence: L‑ornithine‑L‑aspartate (LOLA) substantially lowered serum ammonia and improved hepatic encephalopathy, consistent with enhanced ammonia detoxification.
- Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS
PubMed ID: 24832463
L‑ornithine‑L‑aspartate infusion significantly reduced fasting and post‑prandial venous ammonia after TIPSS — clear evidence of ammonia detoxification in humans.
Mental clarity (25)
- L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy
PubMed ID: 18983791
Improved mental state grade following L‑ornithine‑L‑aspartate in hepatic encephalopathy translates to clearer cognition in that clinical population.
- SGS742: the first GABA(B) receptor antagonist in clinical trials
PubMed ID: 15451390
SGS742 improved attention and working memory measures and is associated with increased aspartate release in animals—good indirect support for cognitive clarity.
- Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia
PubMed ID: 15023571
Sarcosine added to antipsychotics improved cognitive symptoms — strong clinical signal for NMDA‑site modulation producing clearer cognition (indirect to aspartate).
- Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial
PubMed ID: 14734594
Memantine added to donepezil produced modest cognitive improvements in AD patients — notable clinical cognitive outcome though achieved with an NMDA antagonist.
- Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: a pilot double-blind randomized trial
PubMed ID: 12105999
Amantadine produced substantial cognitive/functional improvement in TBI patients (improved MMSE, FIM‑cog) — supports clearer cognition (drug effect; indirect to aspartate).
- A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy
PubMed ID: 21646910
LOLA improved minimal hepatic encephalopathy (cognition) and lowered ammonia—strong evidence for sharpening cognitive clarity in cirrhotic patients.
- A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500)
PubMed ID: 12409683
Large RCT showed small but significant cognitive benefit with memantine — supports cognitive clarity via NMDA modulation.
- The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition
PubMed ID: 21339541
LOLA randomized trial improved CFF, an objective measure of cognitive/attention function in hepatic encephalopathy.
- Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial
PubMed ID: 24074637
Sodium benzoate improved cognitive scores in early Alzheimer's disease — direct cognitive benefit via NMDA-related mechanism (indirect to aspartate).
- Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial
PubMed ID: 25038208
LOLA improved critical flicker frequency and neuropsych tests in minimal hepatic encephalopathy — strong cognitive clarity evidence.
- [Ornithine aspartate and naloxone combined therapy for hepatic encephalopathy affects cognitive function, prognosis, and neuropeptide levels]
PubMed ID: 24025143
Ornithine-aspartate improved cognitive scores in hepatic encephalopathy by lowering blood ammonia — direct evidence for cognitive clarity in that condition.
- Effects of Five Amino Acids (Serine, Alanine, Glutamate, Aspartate, and Tyrosine) on Mental Health in Healthy Office Workers: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
PubMed ID: 35684157
Amino‑acid supplement (including aspartate) improved spatial cognition/selected cognitive scores in recovery after mental work—direct, small study evidence for cognitive clarity benefits.
- Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study
PubMed ID: 9185752
OA improved psychometric test performance in hepatic encephalopathy (direct cognitive clarity benefit from aspartate‑containing therapy).
- Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study
PubMed ID: 9625322
Objective cognitive test improvements (Number-Connection-Test) indicate clearer cognition in treated cirrhotics.
- Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300)
PubMed ID: 12105362
Memantine produced measurable cognitive (ADAS‑cog/MMSE) improvements in vascular dementia — clear NMDA‑related cognitive signal relevant to clarity.
- Abnormal Anterior Cingulate N-Acetylaspartate and Executive Functioning in Treatment-Resistant Depression After rTMS Therapy
PubMed ID: 26025780
ACC NAA rose ~46% in rTMS responders with correlated executive improvements — strong metabolite->cognition link (NAA).
- HIV-associated CD4+/CD8+ depletion in infancy is associated with neurometabolic reductions in the basal ganglia at age 5 years despite early antiretroviral therapy
PubMed ID: 26959509
Lower N‑acetyl‑aspartate in children with delayed ART indicates reduced neuronal integrity/metabolism; this is the most directly relevant study to aspartate‑related brain biochemistry (observational).
- Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine
PubMed ID: 27913408
D‑serine improved auditory plasticity and EEG markers of cortical processing—supports cognitive clarity via NMDA function.
- The effect of D-serine administration on cognition and mood in older adults
PubMed ID: 26933803
D‑serine improved executive/spatial learning errors in older adults—direct NMDA co‑agonist cognitive benefit supporting clarity.
- Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo
PubMed ID: 29727385
LOLA improved psychometric HE score and CFF (objective neurocognitive measures), supporting clearer cognition in HE patients.
- Intravenous versus oral 'L-ornithine-L-aspartate' in overt hepatic encephalopathy: a randomized comparative study
PubMed ID: 38789596
LOLA improved hepatic encephalopathy grade and related cognitive findings in HE patients — moderate, disease‑specific evidence for clearer cognition.
- Procognitive Effects of Adjunctive D-Cycloserine to Intermittent Theta-Burst Stimulation in Major Depressive Disorder: Effets procognitifs de la D-cyclosérine en traitement complémentaire par la stimulation thêta-burst intermittente dans le trouble dépressif caractérisé
PubMed ID: 39470367
D‑cycloserine + iTBS improved working memory measures — mechanism relevant to NMDA/aspartate signaling and cognitive clarity.
- Machine learning and data-driven inverse modeling of metabolomics unveil key processes of active aging
PubMed ID: 40993122
Plasma Asp association with better physical/functional status and metabolic networks plausibly correlates with preserved cognitive function and clarity.
- Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS
PubMed ID: 24832463
LOLA improved psychometric test scores (cognitive clarity) while lowering ammonia in post‑TIPSS patients — direct human evidence.
- Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study
PubMed ID: 17656827
16–24 week memantine trials showed cognitive and global improvements in mild–moderate Alzheimer's—clinical evidence for improved cognitive clarity (drug, not aspartate).
Focus & concentration (25)
- A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy
PubMed ID: 21646910
LOLA improved minimal hepatic encephalopathy outcomes and lowered ammonia—direct evidence of improved cognition/attention/mental clarity in hepatic patients; strong match for improving mental focus in that population.
- Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial
PubMed ID: 14734594
Memantine added to donepezil modestly improved cognition and ADLs in Alzheimer patients — clinical cognition signal via NMDA modulation (indirect to aspartate).
- Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: a pilot double-blind randomized trial
PubMed ID: 12105999
Amantadine produced meaningful cognitive and functional gains in diffuse axonal TBI patients — clinically relevant cognitive improvement (indirect link to aspartate biology).
- Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300)
PubMed ID: 12105362
Memantine (NMDA antagonist) produced modest cognitive improvements in vascular dementia — relevant to NMDA/aspartate neurotransmission and focus.
- D-Cycloserine and performance under different states of anxiety in healthy volunteers
PubMed ID: 17510758
Single‑dose D‑cycloserine improved visuospatial learning under low anxiety—evidence of NMDA‑site modulation enhancing learning/attention.
- L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy
PubMed ID: 18983791
Clinical improvement in mental state grade with L‑ornithine‑L‑aspartate indicates clearer mentation in hepatic encephalopathy, supporting improved focus in that pathological setting.
- Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study
PubMed ID: 9625322
Treatment improved Number-Connection-Test times (objective cognitive improvement), supporting improved mental focus/attention in hepatic encephalopathy.
- Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study
PubMed ID: 9185752
OA infusion improved psychometric (NCT‑A) performance in hepatic encephalopathy (direct cognitive benefit from aspartate‑containing therapy).
- Effects of Five Amino Acids (Serine, Alanine, Glutamate, Aspartate, and Tyrosine) on Mental Health in Healthy Office Workers: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
PubMed ID: 35684157
Small randomized trial of a 5‑amino‑acid supplement (includes aspartate) in healthy workers showed improved motivation and specific cognitive recovery measures—direct, positive evidence (limited sample and combined formulation).
- [Ornithine aspartate and naloxone combined therapy for hepatic encephalopathy affects cognitive function, prognosis, and neuropeptide levels]
PubMed ID: 24025143
Ornithine-aspartate + naloxone improved cognition (HDS/MMSE) and lowered ammonia in hepatic encephalopathy — direct cognitive benefit from an aspartate-containing drug.
- D-alanine added to antipsychotics for the treatment of schizophrenia
PubMed ID: 16154544
D‑alanine (an amino acid) improved negative/cognitive symptoms in schizophrenia—direct cognitive benefit signal.
- SGS742: the first GABA(B) receptor antagonist in clinical trials
PubMed ID: 15451390
SGS742 improved attention/processing speed in MCI and was reported to increase brain aspartate release in animals—strong mechanistic/clinical link to attention.
- Procognitive Effects of Adjunctive D-Cycloserine to Intermittent Theta-Burst Stimulation in Major Depressive Disorder: Effets procognitifs de la D-cyclosérine en traitement complémentaire par la stimulation thêta-burst intermittente dans le trouble dépressif caractérisé
PubMed ID: 39470367
D‑cycloserine + iTBS improved working memory — mechanistic NMDA modulation relevant to Asp as excitatory amino acid.
- Intravenous versus oral 'L-ornithine-L-aspartate' in overt hepatic encephalopathy: a randomized comparative study
PubMed ID: 38789596
LOLA improved encephalopathy grade and related cognitive status in HE patients (clinical improvement in brain function) — moderate, condition‑specific evidence for cognitive benefits.
- Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo
PubMed ID: 29727385
LOLA produced clinically meaningful improvements in psychometric HE scores and critical‑flicker frequency, indicating improved cognitive/attentional function in HE patients.
- The effect of D-serine administration on cognition and mood in older adults
PubMed ID: 26933803
Single oral D‑serine improved aspects of spatial learning/executive function in older adults—direct NMDA co‑agonist cognitive benefit relevant to aspartate/NMDA physiology.
- Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS
PubMed ID: 24832463
LOLA improved psychometric performance in patients after TIPSS — direct human evidence of improved cognitive function related to ammonia lowering.
- Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial
PubMed ID: 25038208
LOLA improved critical flicker frequency and number of abnormal neuropsych tests in minimal hepatic encephalopathy — strong cognitive focus signal.
- Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial
PubMed ID: 24074637
Sodium benzoate improved cognitive scores in early Alzheimer's disease—supports aspects of attention/processing (NMDA-related mechanism, not aspartate).
- An N-methyl-D-aspartate receptor agonist facilitates sleep-independent synaptic plasticity associated with working memory capacity enhancement
PubMed ID: 22355644
D‑cycloserine (an NMDA‑site partial agonist) enhanced wake‑dependent working memory improvements in healthy adults — relevant to NMDA‑related modulation of cognitive focus (pharmacologic, indirect to aspartate).
- The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition
PubMed ID: 21339541
Randomized trial: L‑ornithine‑L‑aspartate improved critical flicker frequency (objective encephalopathy/cognitive measure) in cirrhosis.
- Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia
PubMed ID: 15023571
Sarcosine (glycine‑transporter inhibitor) added to antipsychotics produced cognitive symptom improvements — relevant as an NMDA‑site modulator (indirectly informative for excitatory amino‑acid modulation).
- A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI)
PubMed ID: 17117395
Memantine improved attention and processing speed in older adults with memory complaints—direct cognitive/attention benefit (though memantine is an NMDA antagonist, not aspartate supplementation).
- Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study
PubMed ID: 17656827
Memantine produced short-term cognitive and global improvements in mild–moderate AD versus placebo.
- [Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy]
PubMed ID: 15958319
IV LOLA improved encephalopathy measures — supports better attention/mental clarity.
Immune support (14)
- Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group
PubMed ID: 9738173
Palivizumab directly improved infectious outcomes (RSV) — strong immune-benefit evidence, though unrelated to aspartate supplement itself.
- Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomised trial
PubMed ID: 10209977
Hepatitis A vaccination clearly reduced secondary infections — direct, high‑quality immune outcome (but unrelated to aspartate).
- Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group
PubMed ID: 10051494
Lamivudine induced marked antiviral/biochemical responses in HBV — relevant to immune/viral control (drug effect).
- Prediction of successful outcome in a randomised controlled trial of the long-term efficacy of interferon alpha treatment for chronic hepatitis C
PubMed ID: 10223542
Interferon‑alpha produced durable virological/biochemical responses in HCV — demonstrates immune‑mediated viral control.
- Effect of Hejie decoction on T cell immune state of chronic hepatitis B patients
PubMed ID: 15133849
Reported increased CD4 and decreased CD8 in treated hepatitis B patients — direct immune marker changes.
- [Protective effects of ulinastatin against multiple organic damage after severe burn injury: experimental and clinic studies]
PubMed ID: 16324360
Ulinastatin reduced inflammatory mediators and organ injury after severe burn—direct immune/inflammation effect.
- Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate
PubMed ID: 16947782
Tocilizumab produced strong immunomodulation (CRP/ESR normalization) — clear immune effects.
- Effect of parenteral fish oil lipid emulsion in parenteral nutrition supplementation combined with enteral nutrition support in patients undergoing pancreaticoduodenectomy
PubMed ID: 22699972
Parenteral fish-oil after surgery reduced infections and improved liver tests — direct clinical signal for immune resilience.
- Daily intake of heat-killed Lactobacillus plantarum L-137 improves inflammation and lipid metabolism in overweight healthy adults: a randomized-controlled trial
PubMed ID: 31620886
Heat‑killed L. plantarum L‑137 improved ConA‑induced T‑cell proliferation and reduced seasonal cholesterol rise—direct immune marker improvement.
- Arginine enhances wound healing and lymphocyte immune responses in humans
PubMed ID: 2382229
Human randomized supplementation (arginine‑aspartate) increased lymphocyte mitogenic responses and improved wound collagen—direct immune benefit.
- Arginine stimulates wound healing and immune function in elderly human beings
PubMed ID: 8342121
Elderly randomized double‑blind arginine‑aspartate supplementation markedly boosted wound collagen and lymphocyte responses—strong direct evidence.
- Effects of medium-chain and long-chain triacylglycerols in pediatric surgical patients
PubMed ID: 10869893
TPN with MCT/LCT increased blood lymphocyte percent and improved metabolic markers, indicating improved immune markers in this clinical setting.
- Clinical and biochemical effects of coenzyme Q(10), vitamin E, and selenium supplementation to psoriasis patients
PubMed ID: 19041224
Randomized supplement (included selenium‑aspartate) produced clinical improvement in psoriasis and normalized oxidative immune markers—strongest direct immune evidence in dataset.
- Coenzyme Q(10), vitamin E, selenium, and methionine in the treatment of chronic recurrent viral mucocutaneous infections
PubMed ID: 22079390
A multi‑component nutriceutical including selenium aspartate shortened healing and reduced relapses of recurrent viral lesions; immune benefit observed but cannot be attributed solely to aspartate.
Cell health (12)
- Antifibrotic effect of aloe vera in viral infection-induced hepatic periportal fibrosis
PubMed ID: 22563189
Aloe high-molecular-weight fractions reduced fibrosis biomarkers and ALT/AST in periportal fibrosis patients — supports cellular repair/antifibrotic signals.
- Sulforaphane-rich broccoli sprout extract improves hepatic abnormalities in male subjects
PubMed ID: 26604653
Broccoli sprout extract reduced urinary 8‑OHdG (oxidative DNA damage) and ALT — consistent with reduced oxidative injury and potential facilitation of cellular repair.
- Effect of watercress extract supplementation on lipid profile and oxidative stress markers in overweight people with physical disability: A randomized, double-blind, and placebo-controlled trial
PubMed ID: 33507592
Watercress reduced lipid peroxidation (oxidative stress) markers—supports cellular repair/antioxidant processes.
- Arginine enhances wound healing and lymphocyte immune responses in humans
PubMed ID: 2382229
Oral arginine‑aspartate increased collagen deposition in healthy volunteers' standardized wounds—robust human repair outcome.
- Arginine stimulates wound healing and immune function in elderly human beings
PubMed ID: 8342121
Oral arginine‑aspartate markedly increased wound hydroxyproline and total protein in elderly—direct human evidence of enhanced tissue repair.
- Promotion and acceleration of diabetic ulcer healing by arginine-glycine-aspartic acid (RGD) peptide matrix. RGD Study Group
PubMed ID: 7698046
Topical RGD peptide (contains arginine‑glycine‑aspartic acid motif) markedly increased and accelerated healing of chronic diabetic foot ulcers — strong clinical wound‑repair effect (topical peptide).
- Oral magnesium supplementation as prophylaxis for noise-induced hearing loss: results of a double blind field study
PubMed ID: 8460390
Large RCT showed oral magnesium‑aspartate approximately halved permanent noise‑induced hearing loss—consistent with cellular protection of cochlear structures.
- Oral magnesium intake reduces permanent hearing loss induced by noise exposure
PubMed ID: 8135325
Large RCT: oral magnesium aspartate reduced permanent noise-induced hearing loss, consistent with cellular protection/repair in the cochlea.
- Neuroprotective effects of glycine for therapy of acute ischaemic stroke
PubMed ID: 10629347
Glycine treatment reduced CSF excitatory amino acids with associated improvements in stroke clinical scales and lower short‑term mortality trends — suggests support for recovery/repair after injury.
- Effect of cold blood cardioplegia enriched with potassium-magnesium aspartate during coronary artery bypass grafting
PubMed ID: 17043614
Aspartate‑enriched cardioplegia reduced cardiac troponin rises and improved early myocardial outcomes—evidence of cellular protection/repair.
- Ischemic preconditioning confers antiapoptotic protection during major hepatectomies performed under combined inflow and outflow exclusion of the liver. A randomized clinical trial
PubMed ID: 19575143
Duplicate entry: ischemic preconditioning showed marked reduction in hepatic apoptosis and lowered injury markers — strong tissue protection signal (not aspartate supplementation).
- Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder
PubMed ID: 22676966
Ketamine increased plasma BDNF and enhanced slow‑wave markers of synaptic strength, correlating with rapid mood improvement—evidence for synaptic/ cellular plasticity.
Hormone balance (9)
- Evaluation of in vivo supplementation of 2660 mg D-aspartic acid and 200 mg ubiquinol and 10 mg zinc on different semen parameters in idiopathic male infertility: a randomized double blind placebo controlled study
PubMed ID: 40248985
3‑month trial of D‑aspartic acid (with ubiquinol+zinc) produced a small but significant rise in total testosterone—supports an effect on hormone balance though attribution to D‑aspartic acid alone is limited by combination product.
- Effects of HRT on liver enzyme levels in women with type 2 diabetes: a randomized placebo-controlled trial
PubMed ID: 16817817
Study of combined HRT showing biochemical changes—directly relevant to hormone therapy effects on labs.
- Serum metabolomic profiling reveals potential biomarkers in assessing the management of women with polycystic ovary syndrome: a randomized controlled trial
PubMed ID: 34873082
Measured aspartic acid increases in treated PCOS patients (links to hormone-related metabolic changes) — indirect support for hormone-related effects.
- Effects of feeding green microalgae on ovarian activity, reproductive hormones and metabolic parameters of Boer goats in arid subtropics
PubMed ID: 28532834
Goat feeding study (Dunaliella) increased reproductive hormones (progesterone, estrogen, FSH/LH) — direct hormone effect but non‑human and not aspartate supplementation.
- The influence of orlistat, metformin and diet on serum levels of insulin-like growth factor-1 in obeses women with and without insulin resistance
PubMed ID: 30683825
Study reports IGF‑1 increases with weight‑loss interventions in insulin‑resistant women—directly relevant to systemic hormone (IGF‑1) changes.
- Effect of growth hormone therapy on liver enzyme and other cardiometabolic risk factors in boys with obesity and nonalcoholic fatty liver disease
PubMed ID: 35216556
rhGH raised IGF‑1 and altered BMI/liver enzymes—direct hormone intervention relevant to 'hormone balance'.
- Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial
PubMed ID: 36897180
Fezolinetant is a menopause (vasomotor) therapeutic tied to sex‑hormone symptom management—relevant to hormone outcomes.
- Dose-dependent hormonal effects of toremifene in postmenopausal breast cancer patients
PubMed ID: 10803924
Toremifene produced clear estrogenic biochemical changes (FSH/LH/SHBG) — direct hormonal effects noted in the paper.
- Tribulus terrestris versus placebo in the treatment of erectile dysfunction and lower urinary tract symptoms in patients with late-onset hypogonadism: A placebo-controlled study
PubMed ID: 30253697
Tribulus terrestris trial showed a measurable rise in total testosterone and improved erectile function — indirect evidence for supporting hormone balance (but intervention is not aspartate).
Mood balance (10)
- An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder
PubMed ID: 26807672
Ketamine led to rapid, meaningful antidepressant effects in treatment‑resistant bipolar depression—mood benefit via NMDA axis.
- Ketamine-induced changes in plasma brain-derived neurotrophic factor (BDNF) levels are associated with the resting-state functional connectivity of the prefrontal cortex
PubMed ID: 31680600
Ketamine raised plasma BDNF and produced network changes consistent with plasticity and rapid antidepressant effects — relevant to mood elevation via NMDA/Glutamate‑aspartate pathways.
- Effect of the NMDA receptor partial agonist, d-cycloserine, on emotional processing and autobiographical memory
PubMed ID: 32375905
D‑cycloserine enhanced positive emotional memory specificity — a relatively strong, direct emotional/mnemonic effect via NMDA modulation.
- Effects of phototherapy on biopterin, neopterin, tryptophan, and behavioral neuroinflammatory reaction in patients with post-stroke depression
PubMed ID: 39112627
RCT in post‑stroke depression: phototherapy raised BH4, tryptophan and aspartate and produced marked improvement in depression scores and QoL — direct mood signal concurrent with increased Asp.
- A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression
PubMed ID: 27056608
Repeated IV ketamine produced large sustained antidepressant effects—strong evidence for mood elevation via NMDA pathway (indirect to aspartate signaling).
- Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial
PubMed ID: 23982301
Randomized ketamine trial produced rapid antidepressant effects — strong clinical mood signal, mechanistically via NMDA modulation (indirect to aspartate).
- Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder
PubMed ID: 22676966
Ketamine increased BDNF and sleep slow‑wave markers that correlated with rapid mood improvement in responders.
- Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study
PubMed ID: 22298121
Single IV ketamine produced rapid, robust antidepressant effects in treatment‑resistant depression (clear clinical signal).
- The relevance between symptoms and magnetic resonance imaging analysis of the hippocampus of depressed patients given electro-acupuncture combined with Fluoxetine intervention - A randomized, controlled trial
PubMed ID: 21359920
Electro-acupuncture + fluoxetine produced greater depressive symptom reductions (improved mood) than fluoxetine alone—relevant to mood elevation but not specific to aspartate supplementation.
- An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder
PubMed ID: 19011431
NR2B‑selective NMDA antagonist produced rapid antidepressant effects in treatment‑resistant patients—strong clinical mood effect via NMDA pathway.
Muscle growth (9)
- Usefulness of granular BCAA after hepatectomy for liver cancer complicated with liver cirrhosis
PubMed ID: 15811769
BCAA granules accelerated albumin (protein) recovery after liver resection—direct evidence of supporting protein repletion.
- Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer
PubMed ID: 9816275
PALA (an aspartate analog) inhibited ATCase (pyrimidine synthesis); nucleotide availability directly affects protein/nucleic‑acid synthesis — mechanistic relevance.
- Effects of medium-chain and long-chain triacylglycerols in pediatric surgical patients
PubMed ID: 10869893
TPN regimen improved nitrogen balance—direct nutritional/metabolic outcome tied to protein handling.
- The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men
PubMed ID: 22459616
LGD-4033 increased lean mass in a randomized trial — strong direct signal for muscle growth (though not aspartate-related).
- Long-term effects of aerobic plus resistance training on the adipokines and neuropeptides in nonalcoholic fatty liver disease obese adolescents
PubMed ID: 22932160
Resistance training plus aerobic training produced lean/muscle-supporting metabolic changes in adolescents with NAFLD.
- Chinese Herbal Medicine (Xiaoaiping) Injections for Chemotherapy-Induced Thrombocytopenia: A Randomized, Controlled, Multicenter Clinical Trial
PubMed ID: 31090434
Xiaoaiping improved platelet counts after chemotherapy, indicating improved hematologic/protein‑production recovery.
- Arginine enhances wound healing and lymphocyte immune responses in humans
PubMed ID: 2382229
Human arginine‑aspartate increased hydroxyproline (collagen) and lymphocyte responses—direct effect on protein deposition in wounds.
- Arginine stimulates wound healing and immune function in elderly human beings
PubMed ID: 8342121
Elderly RCT: arginine‑aspartate increased total protein in wound collections (~+98%) and raised serum IGF‑1—strong direct evidence for anabolic/protein production effects.
- Metabolic effects of arginine in a healthy elderly population
PubMed ID: 8551652
Two weeks of oral arginine‑aspartate in elderly raised IGF‑1 and improved nitrogen balance — strong evidence for supporting protein/anabolic status in this setting.
Fertility (8)
- Effects of feeding green microalgae on ovarian activity, reproductive hormones and metabolic parameters of Boer goats in arid subtropics
PubMed ID: 28532834
Goat feeding of Dunaliella microalgae improved ovarian activity and raised reproductive hormones — strong reproductive signal in animals, not aspartate.
- Mechanism of Guilu Erxian ointment based on targeted metabolomics in intervening in vitro fertilization and embryo transfer outcome in older patients with poor ovarian response of kidney-qi deficiency type
PubMed ID: 36742408
Targeted metabolomics found elevated L‑aspartic acid in follicular fluid of older poor ovarian responders and changes after treatment — direct observational link to ovarian environment and fertility biology (not a supplementation trial).
- Improvement of erectile function with Prelox: a randomized, double-blind, placebo-controlled, crossover trial
PubMed ID: 17703218
Prelox (L‑arginine aspartate + Pycnogenol) improved erectile function and increased testosterone in men — significant sexual function/fertility relevance though multi‑ingredient.
- Improvement of seminal parameters with Prelox: a randomized, double-blind, placebo-controlled, cross-over trial
PubMed ID: 19142978
Randomized trial of L-arginine aspartate + Pycnogenol improved semen parameters in infertile men; effect credible but aspartate is in a combination product (confounded).
- Investigation of a complex plant extract for mild to moderate erectile dysfunction in a randomized, double-blind, placebo-controlled, parallel-arm study
PubMed ID: 20184576
Six‑month randomized trial of pine‑bark + L‑arginine aspartate improved erectile function and raised testosterone — clinically meaningful fertility/sexual‑function evidence but product contained multiple actives.
- Sperm quality in men is improved by supplementation with a combination of L-arginine, L-citrullin, roburins and Pycnogenol®
PubMed ID: 25531191
Well-controlled crossover trial of a multi-ingredient supplement containing arginine improved sperm concentration/motility and eNOS activity; aspartate attribution unclear.
- Evaluation of in vivo supplementation of 2660 mg D-aspartic acid and 200 mg ubiquinol and 10 mg zinc on different semen parameters in idiopathic male infertility: a randomized double blind placebo controlled study
PubMed ID: 40248985
D‑aspartic acid (given with ubiquinol+zinc) significantly increased progressive sperm motility and total testosterone over 3 months in infertile men—strongest direct evidence in the dataset for reproductive benefit, though attribution solely to D‑aspartic acid is limited by combination product.
- Serum metabolomic profiling reveals potential biomarkers in assessing the management of women with polycystic ovary syndrome: a randomized controlled trial
PubMed ID: 34873082
Study involved treated PCOS patients; metabolomics showed aspartic acid rises during management — PCOS is directly related to fertility, so this is an indirect link.
Stress resilience (8)
- Valproic acid but not D-cycloserine facilitates sleep-dependent offline learning of extinction and habituation of conditioned fear in humans
PubMed ID: 22992332
Valproic acid and D‑cycloserine affected extinction learning in different states — relevant to mechanisms of stress/emotional memory handling.
- Neurocognitive processes in d-cycloserine augmented single-session exposure therapy for anxiety: A randomized placebo-controlled trial
PubMed ID: 32229324
D‑cycloserine before exposure therapy improved short‑term recovery and reduced threat bias/amygdala reactivity—strongest direct signal for stress handling.
- Augmenting extinction learning with D-cycloserine reduces return of fear: a randomized, placebo-controlled fMRI study
PubMed ID: 31634897
D‑cycloserine before extinction training reduced return of fear and changed hippocampal/amygdala responses — direct experimental support for improved stress/fear extinction handling via NMDA modulation.
- Dextromethorphan reduces immediate and late postoperative analgesic requirements and improves patients' subjective scorings after epidural lidocaine and general anesthesia
PubMed ID: 12032024
Preincision dextromethorphan halved opioid/NSAID needs and improved pain/sedation — strong analgesic/stress‑reduction signal (indirectly relevant to aspartate/NMDA).
- Dextromethorphan for the reduction of immediate and late postoperative pain and morphine consumption in orthopedic oncology patients: a randomized, placebo-controlled, double-blind study
PubMed ID: 12209704
Preincision dextromethorphan markedly reduced postoperative pain, opioid need, and sedation — substantial clinical stress/strain mitigation via NMDA blockade.
- Postoperative intramuscular dextromethorphan injection provides pain relief and decreases opioid requirement after modified radical mastectomy
PubMed ID: 12678512
IM dextromethorphan reduced opioid use and shortened bed rest — clinically meaningful reduction in surgical stress response (indirect NMDA/aspartate link).
- Premedication with dextromethorphan provides posthemorrhoidectomy pain relief
PubMed ID: 10789747
Premedication with dextromethorphan delayed and reduced postoperative opioid need and lowered worst pain — reduces perioperative stress (indirect NMDA/aspartate relation).
- Antioxidant treatment during liver resection for alleviation of ischemia-reperfusion injury
PubMed ID: 9684133
Perioperative antioxidant vitamins improved coagulation and limited transaminase rise after ischemia — relevant to handling surgical oxidative stress.
Nutrient uptake (7)
- Effect of multivitamin supplementation on the homocysteine and methylmalonic acid blood concentrations in women over the age of 60 years
PubMed ID: 15309436
Multivitamin supplementation raised serum B‑vitamin levels and lowered metabolic markers — clear evidence of improved nutrient status/uptake in elderly women.
- Can one really measure magnesium deficiency using the short-term magnesium loading test?
PubMed ID: 10583708
Direct evidence: IV Mg-aspartate load showed percentage magnesium retention that reflected magnesium status and changed after oral Mg-aspartate therapy—clear effect on mineral uptake/retention.
- Nutritional magnesium supplementation does not change blood pressure nor serum or muscle potassium and magnesium in untreated hypertension. A double-blind crossover study
PubMed ID: 7786691
Oral magnesium (given as a supplement) produced a clear rise in urine magnesium — direct evidence of absorption and systemic uptake.
- Gut Permeability Might be Improved by Dietary Fiber in Individuals with Nonalcoholic Fatty Liver Disease (NAFLD) Undergoing Weight Reduction
PubMed ID: 30453660
Dietary fiber intervention markedly reduced zonulin (gut permeability marker), directly indicating improved gut barrier/nutrient handling potential.
- Dietary chlorogenic acid regulates gut microbiota, serum-free amino acids and colonic serotonin levels in growing pigs
PubMed ID: 29141471
Chlorogenic acid raised serum free aspartic acid and increased gut microbiota diversity in pigs — direct evidence of altered nutrient/AA availability (animal model).
- A dose-response study of vitamin D3 supplementation in healthy Chinese: a 5-arm randomized, placebo-controlled trial
PubMed ID: 25694350
Vitamin D3 produced clear dose‑dependent increases in serum 25(OH)D — direct evidence of improved nutrient (vitamin D) status with supplementation.
- Efficacy and safety of ferrous asparto glycinate in the management of iron deficiency anaemia in pregnant women
PubMed ID: 24959663
Ferrous asparto glycinate led to larger increases in Hb and ferritin than comparator, consistent with improved iron uptake/bioavailability.
Energy & Fatigue (6)
- Efficacy and safety of ferrous asparto glycinate in the management of iron deficiency anaemia in pregnant women
PubMed ID: 24959663
Correction of iron‑deficiency anemia with ferrous asparto glycinate produced larger Hb increases versus comparator, a plausible mechanism to reduce fatigue.
- Safety and Efficacy of Mild Moxibustion on Cancer-Related Fatigue in Non-Small-Cell Lung Cancer Patients Undergoing Chemotherapy
PubMed ID: 35912144
Trial showed reduced patient‑reported fatigue (RPFS‑CV) with mild moxibustion—direct effect on tiredness.
- Amino acid-enriched glucose-insulin-potassium infusion improves hemodynamic function after coronary bypass surgery. A double-blind study in patients with unstable angina and/or compromised left ventricular function
PubMed ID: 7787408
Amino-acid–enriched GIK (including aspartate) produced sizable acute hemodynamic improvements (cardiac index), plausibly supporting systemic energy delivery in that setting.
- Machine learning and data-driven inverse modeling of metabolomics unveil key processes of active aging
PubMed ID: 40993122
Plasma aspartate was the top metabolite associated with better physical performance and activity in very‑old adults — supportive for systemic energy/physical capacity.
- An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder
PubMed ID: 26807672
Ketamine produced clinically meaningful fatigue reductions vs placebo in bipolar depression—direct clinical signal for reduced tiredness.
- Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study
PubMed ID: 9185752
Ammonia-lowering OA improved psychometrics in encephalopathy, plausibly reducing mental fatigue.
Exercise recovery (6)
- Arginine enhances wound healing and lymphocyte immune responses in humans
PubMed ID: 2382229
Oral arginine‑aspartate increased collagen deposition in wounds and lymphocyte responses—supports repair processes that aid recovery.
- Usefulness of granular BCAA after hepatectomy for liver cancer complicated with liver cirrhosis
PubMed ID: 15811769
BCAA granules sped albumin recovery after hepatectomy — strong nutrition/protein recovery signal relevant to muscle repair.
- A double-blinded randomised controlled study of the value of sequential intravenous and oral magnesium therapy in patients with chronic low back pain with a neuropathic component
PubMed ID: 23384256
Sequential IV+oral magnesium reduced pain and improved lumbar mobility at 6 months — supports functional recovery.
- Effect of astaxanthin supplementation on muscle damage and oxidative stress markers in elite young soccer players
PubMed ID: 22828460
Astaxanthin attenuated post‑exercise CK and AST rises and oxidative changes—direct evidence of reduced muscle damage/accelerated recovery.
- Effect of cold blood cardioplegia enriched with potassium-magnesium aspartate during coronary artery bypass grafting
PubMed ID: 17043614
Aspartate‑containing cardioplegia reduced cardiac injury markers and improved early cardiac recovery.
- Arginine stimulates wound healing and immune function in elderly human beings
PubMed ID: 8342121
Elderly arginine‑aspartate increased wound protein and hydroxyproline and raised IGF‑1—supports tissue protein synthesis relevant to recovery.
Sleep quality (2)
- Safety and Efficacy of N-SORB(®), a Proprietary KD120 MEC Metabolically Activated Enzyme Formulation: A Randomized, Double-Blind, Placebo-Controlled Study
PubMed ID: 30971174
Study reported PSQI/quality‑of‑sleep improvements with multienzyme product over 90 days.
- Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance
PubMed ID: 28820468
Resveratrol adjunct in HCV patients significantly improved PSQI (sleep quality) vs control — direct sleep benefit but not aspartate.
Endurance (1)
- Machine learning and data-driven inverse modeling of metabolomics unveil key processes of active aging
PubMed ID: 40993122
Aspartate was the strongest metabolite marker of better physical performance in very‑old adults — directly supportive for stamina/endurance capacity.
Workout performance (1)
- Machine learning and data-driven inverse modeling of metabolomics unveil key processes of active aging
PubMed ID: 40993122
Aspartate emerged as the strongest biomarker associated with better physical performance in very‑old adults — supportive for exercise capacity.
Forms of Aspartate
The 2 forms a label may print instead of Aspartate. Each is a different substance with its own identifier, and none of them has research of its own — the studies are the ones on this page.
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with Aspartate
Search all961 products whose verified label declares Aspartate — not every bottle that mentions it in a title.
Being studied right now
Recruiting clinical trials registered on ClinicalTrials.gov. A trial in progress has no result yet — this is what the field is asking, not what it found.